By Counterforce Health Team in Imbruvica (ibrutinib) — 08 Dec 2025

The Complete Requirements Checklist to Get Imbruvica (ibrutinib) Covered by Cigna in Ohio

Answer Box: Getting Imbruvica (ibrutinib) Covered by Cigna in Ohio

Who's eligible: Adults with CLL/SLL, Waldenström macroglobulinemia, or chronic graft-versus-host disease under oncologist care. Fastest path: Submit Cigna's oncology prior authorization with complete pathology, prior treatment history, and medical necessity letter citing FDA labeling and NCCN guidelines. First step today: Call Cigna member services to confirm your plan requires Accredo Specialty Pharmacy and download the current PA form from your provider portal. Most approvals take 5-7 business days; expedited review available for urgent cases.

Who Should Use This Checklist
Member & Plan Basics
Clinical Criteria Requirements
Coding & Documentation Hygiene
Your Complete Documentation Packet
Submission Mechanics
Specialty Pharmacy Requirements
After Submission: What to Track
Appeals Playbook for Ohio
Common Denial Pitfalls & How to Avoid Them
Printable One-Page Checklist

Who Should Use This Checklist

This comprehensive requirements checklist is designed for patients and their healthcare teams navigating Cigna's prior authorization process for Imbruvica (ibrutinib) in Ohio. You'll benefit from this guide if you:

Have been diagnosed with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia, or chronic graft-versus-host disease
Need to submit an initial prior authorization request to Cigna
Received a denial and want to ensure your appeal is bulletproof
Are transferring from another insurer and need continuation approval

Expected outcome: Following this checklist increases your approval odds significantly by ensuring you meet all of Cigna's documented criteria and avoid the most common submission errors that trigger automatic denials.

Member & Plan Basics

Before diving into clinical requirements, verify these foundational elements:

✓ Active Coverage Verification

Member ID and group number from your current Cigna card
Plan type: Commercial, Medicare Advantage, or Medicaid managed care
Effective dates of coverage (Imbruvica requires continuous coverage)
Deductible status: Many plans require meeting deductible before specialty drug coverage

Tip: Log into myCigna.com to verify your current benefits and formulary status for Imbruvica.

✓ Prior Authorization Requirements

Cigna requires prior authorization for all Imbruvica formulations in 2025, including:

140mg capsules (preferred formulation)
280mg and 420mg tablets
Oral suspension for pediatric cGVHD patients

✓ Step Therapy Considerations

Some Cigna plans require trying preferred BTK inhibitors first:

Brukinsa (zanubrutinib) - often preferred first-line for CLL/SLL
Calquence (acalabrutinib) - may be required before Imbruvica in certain plans

Clinical Criteria Requirements

Cigna's oncology prior authorization policy for Imbruvica follows FDA labeling and NCCN guidelines closely. Here's what you must demonstrate:

✓ FDA-Approved Indications

Your diagnosis must match one of these approved uses:

Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults
Waldenström macroglobulinemia in adults
Chronic graft-versus-host disease in adults and children ≥1 year after failure of ≥1 systemic therapy

✓ Prescriber Requirements

Board-certified hematologist or medical oncologist
Active NPI number and DEA registration
Documented experience treating your specific condition

✓ Treatment History Documentation

For treatment-naïve patients:

Confirmation that Imbruvica is appropriate first-line therapy per NCCN guidelines
Documentation of high-risk features (del(17p), TP53 mutation, unmutated IGHV) if relevant

For relapsed/refractory patients:

Detailed history of prior systemic regimens with:
- Specific drugs, doses, and treatment duration
- Best response achieved (CR, PR, SD, PD)
- Reason for discontinuation (progression, toxicity, intolerance)
- Time to progression or relapse

✓ Safety Assessment

Document baseline evaluation including:

Complete blood count and comprehensive metabolic panel
Hepatitis B screening (risk of reactivation)
Cardiac history and current rhythm assessment
Bleeding risk factors and concurrent anticoagulation
Performance status (ECOG 0-2 typically required)

Coding & Documentation Hygiene

Proper medical coding is crucial for approval. Use these specific codes:

✓ ICD-10 Diagnosis Codes

C91.10 - Chronic lymphocytic leukemia of B-cell type, not having achieved remission
C91.11 - Chronic lymphocytic leukemia of B-cell type, in remission
C91.12 - Chronic lymphocytic leukemia of B-cell type, in relapse
C88.0 - Waldenström macroglobulinemia
D89.811 - Chronic graft-versus-host disease

✓ Drug Identification

NDC numbers: Varies by strength and manufacturer
J-code: J9057 for injection (rarely used for oral Imbruvica)
Dosing: Typically 420mg once daily continuously until progression

✓ Supporting Codes

Include relevant comorbidity codes that support medical necessity:

High-risk cytogenetics (if documented separately)
Performance status indicators
Prior treatment complications

Your Complete Documentation Packet

Assemble these documents before submission to avoid delays:

✓ Core Clinical Documents

Pathology report confirming diagnosis with immunophenotyping
FISH analysis or cytogenetics showing prognostic markers
Bone marrow biopsy (if performed)
Flow cytometry results
Recent imaging (CT scans showing disease extent)

✓ Treatment History Records

Prior regimen summary with dates, responses, and toxicities
Hospital discharge summaries for treatment-related complications
Laboratory trends showing disease progression or response

✓ Current Clinical Status

Recent office visit notes (within 30 days)
Current laboratory values (CBC, chemistry, LDH, beta-2 microglobulin)
Performance status assessment

✓ Medical Necessity Letter

Your oncologist should include these key elements:

Problem statement: Clear diagnosis with staging and risk stratification

Treatment rationale: Why Imbruvica is medically necessary for this specific patient, citing:

FDA labeling for the indication
NCCN guideline recommendations (Category 1 or 2A)
Patient-specific factors favoring BTK inhibitor therapy

Safety plan: Monitoring schedule and toxicity management approach

Duration: Continuous therapy until progression or unacceptable toxicity

Submission Mechanics

Follow these steps to submit your prior authorization correctly:

✓ Use Current Forms

Download the latest Cigna oncology prior authorization form from your provider portal
Forms are updated regularly - verify you have the 2025 version
Complete all required fields to avoid automatic rejection

✓ Submission Method

Provider portal preferred: Most Cigna plans accept electronic submissions through the provider portal

Fax backup: If portal submission fails, fax to the number listed on your specific plan's PA form (verify current fax number)

✓ Required Fields That Cause Rejections

Member ID and group number (exact match to insurance card)
Prescriber NPI number
Diagnosis codes (ICD-10)
Requested quantity and days supply
Clinical trial history (if applicable)

Note: Incomplete forms are automatically denied without clinical review.

Specialty Pharmacy Requirements

Most Cigna plans require Imbruvica to be dispensed through designated specialty pharmacies:

✓ Accredo Specialty Pharmacy

Primary vendor for most Cigna plans using Express Scripts
Phone: Contact through your plan's member services
Services: Home delivery, clinical support, copay assistance coordination

✓ Transfer Process

New prescription route (recommended):
- Have your oncologist send new e-prescription directly to Accredo
- Include your Cigna member ID and preferred shipping address
Prescription transfer route:
- Call Accredo to request transfer from current pharmacy
- Provide current pharmacy contact information

✓ Verification Steps

Confirm Accredo received the prescription
Verify insurance authorization is in place
Schedule delivery (typically 2-3 business days after approval)

After Submission: What to Track

Stay organized with these tracking steps:

✓ Confirmation Documentation

Submission confirmation number from portal or fax confirmation
Date and time of submission
Contact information for follow-up

✓ Status Check Schedule

Day 3: Call to confirm receipt and completeness
Day 5: Check determination status
Day 7: If no decision, request expedited review if clinically appropriate

✓ Record Everything

Phone call logs with representative names and reference numbers
Email confirmations of status updates
Decision letters (approval or denial)

Appeals Playbook for Ohio

If your initial request is denied, Ohio provides strong consumer protections:

✓ Internal Appeals with Cigna

First-level internal appeal:

Deadline: 180 days from denial date
Timeline: Decision within 30 days (72 hours if expedited)
Submit to: Address on denial letter or member portal

Second-level internal appeal:

Available if first-level appeal is denied
Same timeline and submission process

✓ External Review in Ohio

After exhausting internal appeals, Ohio residents can request external review:

Timeline: 180 days from final internal denial to request external review

Process: File request with your health plan, which notifies the Ohio Department of Insurance

Decision authority: Independent Review Organization (IRO) with medical experts

Binding decision: If IRO overturns denial, Cigna must cover the treatment

Ohio-specific advantage: The Ohio Department of Insurance can independently determine external review eligibility even if Cigna initially claims your case doesn't qualify.

✓ Getting Help in Ohio

Ohio Department of Insurance Consumer Services: 1-800-686-1526
UHCAN Ohio (nonprofit advocacy): Provides consumer assistance with appeals
External Review Request Form: Available on ODI website

Common Denial Pitfalls & How to Avoid Them

Learn from the most frequent rejection reasons:

Denial Reason	How to Fix	Prevention Strategy
Incomplete prior therapy documentation	Submit detailed treatment history with dates, doses, responses	Create comprehensive treatment timeline before submission
Missing pathology confirmation	Include flow cytometry and FISH results	Ensure pathologist reports include immunophenotyping
Step therapy not completed	Document contraindication or failure of preferred BTK inhibitors	Address step therapy requirements proactively in medical necessity letter
Off-label use not supported	Cite NCCN compendium or FDA guidance for indication	Stick to FDA-approved indications when possible
Safety concerns not addressed	Include monitoring plan and toxicity management strategy	Document baseline cardiac and bleeding risk assessment

Printable One-Page Checklist

Before Submission:

Active Cigna coverage verified
Current PA form downloaded
Pathology report with immunophenotyping
FISH/cytogenetics results
Complete prior treatment history
Medical necessity letter with NCCN citations
Baseline safety labs and cardiac assessment
Prescriber NPI and DEA numbers confirmed

During Submission:

All form fields completed
Correct member ID and group number
Appropriate ICD-10 codes used
Submission confirmation obtained
Follow-up schedule established

After Submission:

Status checked on day 3 and 5
Decision letter received and reviewed
If denied, appeal timeline noted (180 days)
Specialty pharmacy coordination completed

If Denied:

Denial reason identified and addressed
Internal appeal submitted within 180 days
Additional clinical documentation gathered
External review option noted for Ohio residents

About Counterforce Health

Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into successful appeals. Our platform analyzes denial letters, plan policies, and clinical notes to create targeted, evidence-backed appeals that align with each payer's specific requirements. For complex cases like Imbruvica approvals, we identify the exact denial basis and draft point-by-point rebuttals using FDA labeling, peer-reviewed studies, and specialty guidelines.

FAQ

How long does Cigna prior authorization take for Imbruvica in Ohio? Standard review takes 5-7 business days. Expedited review (when delay would jeopardize health) must be decided within 24-72 hours.

What if Imbruvica is non-formulary on my Cigna plan? Request a formulary exception with medical necessity documentation. Your oncologist must demonstrate why formulary alternatives are inappropriate.

Can I request expedited appeal if my initial PA is denied? Yes, if treatment delay would seriously endanger your health. Your oncologist must certify the urgent medical need.

Does step therapy apply if I was stable on Imbruvica with my previous insurer? Continuation of therapy may override step therapy requirements if your doctor documents that switching would be medically inappropriate.

What's the difference between internal and external review in Ohio? Internal review is conducted by Cigna's medical staff. External review uses independent medical experts assigned by the Ohio Department of Insurance and is binding on the insurer.

Sources & Further Reading

Disclaimer: This guide is for educational purposes and does not constitute medical or legal advice. Coverage decisions depend on your specific plan terms and clinical circumstances. Always consult with your healthcare provider and insurance plan for personalized guidance. For questions about Ohio insurance regulations, contact the Ohio Department of Insurance at 1-800-686-1526.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.